Pfizer Inc. news

   Watch this stock
Showing stories 11 - 20 of about 183   

Articles published

PFE 33.24 +0.15 (0.45%)
price chart
Stocks to Watch: Tesla, Pfizer, Paychex, Campbell Soup
Among the companies with shares expected to trade actively in Wednesday's session are Tesla Motors Inc.TSLA -1.94%, Pfizer Inc.PFE -2.06% and Paychex Inc.PAYX -0.31%. Tesla launched its new Model X electric SUV Tuesday evening with CEO Elon ...
Shares of Pfizer, Inc. (NYSE:PFE) Sees Large Inflow of Net Money
Pfizer, Inc. (NYSE:PFE) witnessed a selling pressure and the shares last traded with a loss of -0.03 points or -0.09% at $33.05.
Pfizer, Inc. (NYSE:PFE) Analyst Price Target  Money Flow Index
Pfizer Downgraded by Vetr Inc. (PFE)  Dakota Financial News
On the Radar: Keep an eye on these stocks: Pfizer Inc (NYSE:PFE), GoPro Inc ...
Pfizer Inc (NYSE:PFE) decreased -0.60% during the last trading session to settle at $33.09. Its market capitalization has now reached $205.31 Billion.
Pfizer Edges Outlook Higher to Factor in Hospira
Pfizer acquired smaller rival Hospira in a $16 billion deal that closed earlier this month. The acquisition is expected to transform the pharmaceutical company into a leading player in the emerging market for lower-priced knockoffs of costly biotech drugs.
Pfizer (PFE) Boosts FY15 Outlook Following Completion of Hospira Acquisition
Pfizer lifts outlook to factor in Hospira purchase  MarketWatch
Company Shares of Pfizer, Inc. (NYSE:PFE) Rally 3.73%
Shares of Pfizer, Inc. (NYSE:PFE) rose by 3.73% in the past week and 5.45% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 2.67% and the outperformance increases to 3.82% for the last 4 weeks.
Morning Buzzers: Pfizer Inc. (NYSE:PFE), BP plc (ADR) (NYSE:BP), AT&T ...  News Oracle
Drug Manufacturer Most Active- Pfizer Inc. (NYSE:PFE), Merck & Co. Inc ...  StreetWise Report (press release)
Eli Lilly and Co (LLY) Breast Cancer Drug May Challenge Pfizer Inc. Ibrance
Eli Lilly and Co (NYSE:LLY) on Thursday received Breakthrough Therapy status for its breast cancer drug candidate, abemaciclib, from the Food and Drug Administration (FDA).
Pfizer Inc. Announces Results of Early Tenders and Consents in Exchange Offers
NEW YORK, Sep 18, 2015 (BUSINESS WIRE) -- Pfizer Inc. (“Pfizer”) PFE, +1.17% announced today that, as of 5:00 p.m., New York City time, on September 17, 2015 (the “Early Consent Date”), the aggregate principal amounts of each series of notes listed in ...
Active Stocks Trader's Round Up: Nabors Industries Ltd. (NYSE:NBR), Pfizer Inc ...
Nabors Industries Ltd. (NYSE:NBR), finished its last exchange with 1.54% pick up, and shut at $11.86. Nabors Industries Ltd., together with its helpers, gives boring and apparatus administrations.
Pfizer Inc. (NYSE:PFE) is a Buy at Current Levels – Jim Cramer
Pfizer Inc. (NYSE:PFE)'s presence in the cancer drug space was almost non-existent until a few years back. The bulk of PFE's profits came from just two drugs - Viagra and Lipitor.
Pfizer Inc (NYSE:PFE) Stock Improved to Overweight at Morgan Stanley from ...
Pfizer Inc (NYSE:PFE) Upgraded at Morgan Stanley to Overweight from Equal ...
Pfizer, Inc. (NYSE:PFE) Handed a Crowd Sourced Rating of 3.75
Shares of Pfizer, Inc. (NYSE:PFE) have been given an average rating of 3.75 according to Closing Bell compiles crowd-sourced stock ratings provided by independent analysts, investors, traders and students.